---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-26-000029"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2026-08-06T20:18:50+00:00"
generated_at: "2026-08-06T20:20:52.639937+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q2 net loss $13.1M; Phase 3 T1D trial enrollment to complete Q3 2026

## Summary
- Net loss of $13.1M ($1.05 per share) vs $6.0M loss ($0.92) in Q2 2025; R&D spend rose to $8.8M from $4.1M.
- Cash and equivalents $86.6M at June 30, 2026; company expects runway through CATT1 topline data readout.
- Phase 3 CATT1 trial for cadisegliatin in type 1 diabetes expected to complete enrollment in Q3 2026.
- Phase 2a Hybrid CATT1 trial (hybrid closed-loop) to initiate before year-end 2026; KOL event planned Q4 2026.
- Six-month revenue of $36.8M (vs $0 in prior year) from a milestone; net income of $11.1M for H1 2026.

## SEC filing metadata
- accession: 0001641489-26-000029
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2026-08-06T20:18:50+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/0001641489-26-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148926000029/vtvt-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-26-000029
- JSON: https://secwatch.observer/filing/0001641489-26-000029.json
- Plain text: https://secwatch.observer/filing/0001641489-26-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.